Second-trimester fetal thymic-thoracic ratio in pregnancies treated with levothyroxine for elevated first-trimester TSH: a retrospective case-control study
Abstract
Objective: Maternal thyroid dysfunction during pregnancy has been associated with adverse fetal and obstetric outcomes; however, the relationship between early pregnancy TSH elevation, levothyroxine treatment, and fetal thymic development remains unclear. This study aimed to compare second-trimester fetal thymic-thoracic ratio (TTR) values between pregnancies receiving levothyroxine after elevated first-trimester thyroid-stimulating hormone (TSH) levels and healthy controls. Methods: This retrospective case-control study included 109 pregnant women who underwent second-trimester obstetric ultrasonography between February 2023 and December 2024. Pregnancies treated with levothyroxine after first-trimester TSH levels ≥2.5 mIU/L (n=43) were compared with healthy controls without thyroid disease or pregnancy-related complications (n=66). Fetal thymic-thoracic ratio measurements were obtained from stored ultrasound images using the method described by Chaoui et al. Continuous variables were compared using the Mann–Whitney U test. Results: No statistically significant difference was observed in fetal thymic-thoracic ratio values between the levothyroxine-treated group and the healthy control group (median TTR: 0.420 [0.345–0.445] vs. 0.395 [0.323–0.450], respectively; p=0.483). Similarly, no significant differences were found between the groups regarding maternal age, gestational age at examination, thymic diameter, thoracic diameter, BMI, or smoking status (all p>0.05). Conclusion: Second-trimester fetal TTR values did not differ significantly between healthy controls and pregnancies treated with levothyroxine after elevated first-trimester TSH. These preliminary findings suggest that early-treated maternal TSH elevation may not be associated with measurable alterations in fetal thymic size during the second trimester. However, the retrospective design, incomplete characterization of thyroid status (including free T4, thyroid antibodies, levothyroxine dose, and confirmation of euthyroidism), and limited statistical power preclude definitive conclusions regarding the effect of treatment. Further prospective, adequately powered longitudinal studies with complete thyroid function data are needed to clarify this relationship.
Related
- Maternal Recognition of Ultrasound-Observed Fetal Movements Among Pregnancies in the Third Trimester: Concordance, Directional Discrepancies, and Associated Factors
- Should glucose screening be repeated for large-for-gestational-age fetuses in the third trimester of non-diabetic pregnancies? A scoping review.
- Mid-Trimester Cervical Length Screening in Routine Practice: Short-Cervix Prevalence, Preterm Birth and the Shift of the Progesterone Counselling Threshold from 20 to 25 mm in a 15-Year Single-Centre Cohort of 20,168 Singleton Pregnancies
- Serum neudesin is elevated in pregnancies complicated by pregestational type 2 diabetes: an exploratory cross-sectional controlled study
- Comparative Analysis of Maternal and Neonatal Outcomes in Teenage and Adult Pregnancies: A Retrospective Study From Western India
BibTeX
@article{demir2026secondtrimester,
title = {{Second-trimester fetal thymic-thoracic ratio in pregnancies treated with levothyroxine for elevated first-trimester TSH: a retrospective case-control study}},
author = {Fatma Nazlı Demir and Zeycan Kübra Cevval and Umutcan Kayıkçı},
journal = {Revista Brasileira de Ginecologia e Obstetrícia},
year = {2026},
month = oct,
doi = {10.61622/rbgo/2026rbgo80},
url = {https://doi.org/10.61622/rbgo/2026rbgo80},
note = {CC BY},
}
RIS
TY - JOUR
TI - Second-trimester fetal thymic-thoracic ratio in pregnancies treated with levothyroxine for elevated first-trimester TSH: a retrospective case-control study
AU - Fatma Nazlı Demir
AU - Zeycan Kübra Cevval
AU - Umutcan Kayıkçı
PY - 2026
DA - 2026/10/30
JO - Revista Brasileira de Ginecologia e Obstetrícia
DO - 10.61622/rbgo/2026rbgo80
UR - https://doi.org/10.61622/rbgo/2026rbgo80
AB - Objective: Maternal thyroid dysfunction during pregnancy has been associated with adverse fetal and obstetric outcomes; however, the relationship between early pregnancy TSH elevation, levothyroxine treatment, and fetal thymic development remains unclear. This study aimed to compare second-trimester fetal thymic-thoracic ratio (TTR) values between pregnancies receiving levothyroxine after elevated first-trimester thyroid-stimulating hormone (TSH) levels and healthy controls. Methods: This retrospective case-control study included 109 pregnant women who underwent second-trimester obstetric ultrasonography between February 2023 and December 2024. Pregnancies treated with levothyroxine after first-trimester TSH levels ≥2.5 mIU/L (n=43) were compared with healthy controls without thyroid disease or pregnancy-related complications (n=66). Fetal thymic-thoracic ratio measurements were obtained from stored ultrasound images using the method described by Chaoui et al. Continuous variables were compared using the Mann–Whitney U test. Results: No statistically significant difference was observed in fetal thymic-thoracic ratio values between the levothyroxine-treated group and the healthy control group (median TTR: 0.420 [0.345–0.445] vs. 0.395 [0.323–0.450], respectively; p=0.483). Similarly, no significant differences were found between the groups regarding maternal age, gestational age at examination, thymic diameter, thoracic diameter, BMI, or smoking status (all p>0.05). Conclusion: Second-trimester fetal TTR values did not differ significantly between healthy controls and pregnancies treated with levothyroxine after elevated first-trimester TSH. These preliminary findings suggest that early-treated maternal TSH elevation may not be associated with measurable alterations in fetal thymic size during the second trimester. However, the retrospective design, incomplete characterization of thyroid status (including free T4, thyroid antibodies, levothyroxine dose, and confirmation of euthyroidism), and limited statistical power preclude definitive conclusions regarding the effect of treatment. Further prospective, adequately powered longitudinal studies with complete thyroid function data are needed to clarify this relationship.
SN - 1806-9339
SN - 0100-7203
ER -